Table of Content
1. INTRODUCTION
1.1. OVERVIEW OF THE SPINE BIOLOGICS MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL SPINE BIOLOGICS MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6. PORTER’S FIVE FORCES MATRIX
2.3. GLOBAL SPINE BIOLOGICS MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. GLOBAL SPINE BIOLOGICS MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.2. RESTRAINTS
4.3.3. OPPURTUNITIES
4.3.4. THREATS
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. SPINE BIOLOGICS MARKET, BY PRODUCT TYPE
5.1. OVERVIEW
5.2. BONE GROWTH SUBSTITUTES
5.2.1. DEMINERALIZED BONE MATRIX (DBM)
5.2.2. BONE MORPHOGENETIC PROTEINS (BMP)
5.2.3. SYNTHETIC BONE GRAFTS
5.3. BONE ALLOGRAFTS
5.4. PLATELET RICH PLASMA (PRP)
5.5. BONE MARROW ASPIRATE CONCENTRATE (BMAC)
6. SPINE BIOLOGICS MARKET, BY SURGERY TYPE
6.1. OVERVIEW
6.2. ANTERIOR CERVICAL DISECTOMY AND FUSION (ACDF)
6.3. TRANSFORAMENAL LUMBAR INTERBODY FUSION (TLIF)
6.4. ANTERIOR LUMBAR INTERBODY FUSION (ALIF)
6.5. LATERAL LUMBAR INTERBODY FUSION (LLIF)
6.6. OTHERS
7. SPINE BIOLOGICS MARKET, BY END USER
7.1. OVERVIEW
7.2. HOSPITALS
7.3. SPINAL SURGERY CENTERS
7.4. ORTHOPEDIC CLINICS
7.5. OTHERS
8. SPINE BIOLOGICS MARKET, BY GEOGRAPHY
8.1. COUNTRYWISE SPINE BIOLOGICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
8.1.1. NORTH AMERICA
8.1.1.1. U.S.
8.1.1.2. CANADA
8.1.1.3. MEXICO
8.1.2. EUROPE
8.1.2.1. GERMANY
8.1.2.2. FRANCE
8.1.2.3. U.K.
8.1.2.4. ITALY
8.1.2.5. SPAIN
8.1.2.6. RUSSIA
8.1.2.7. TURKEY
8.1.2.8. BELGIUM
8.1.2.9. NETHERLANDS
8.1.2.10. SWITZERLAND
8.1.2.11. REST OF EUROPE
8.1.3. ASIA-PACIFIC (APAC)
8.1.3.1. JAPAN
8.1.3.2. CHINA
8.1.3.3. SOUTH KOREA
8.1.3.4. INDIA
8.1.3.5. AUSTRALIA
8.1.3.6. SINGAPORE
8.1.3.7. THAILAND
8.1.3.8. MALAYSIA
8.1.3.9. INDONESIA
8.1.3.10. PHILIPPINES
8.1.3.11. REST OF APAC
8.1.4. LATIN AMERICA
8.1.4.1. BRAZIL
8.1.4.2. REST OF LATIN AMERICA
8.1.5. MIDDLE EAST AND AFRICA
8.1.5.1. SOUTH AFRICA
8.1.5.2. REST OF MIDDLE EAST AND AFRICA
8.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
9. SPINE BIOLOGICS MARKET: COMPETITIVE LANDSCAPE
9.1. GLOBAL SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
9.2. U.S. SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
9.3. EUROPE SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
9.4. APAC SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
9.5. SOUTH AMERICA SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
9.6. MIDDLE EAST AND AFRICA SPINE BIOLOGICS MARKET: COMPANY SHARE ANALYSIS
9.7. MERGERS & ACQUISITIONS
9.8. NEW PRODUCT DEVELOPMENT & APPROVALS
9.9. EXPANSIONS
9.10. REGULATORY CHANGES
9.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
10. SPINE BIOLOGICS MARKET, COMPANY PROFILES
10.1. APPLIED BIOLOGICS
10.1.1. OVERVIEW
10.1.2. SWOT ANALYSIS
10.1.3. PRODUCT PORTFOLIO
10.1.4. REVENUE ANALYSIS
10.1.5. ANALYSTS VIEW
10.2. ARTHREX, INC.
10.2.1. OVERVIEW
10.2.2. SWOT ANALYSIS
10.2.3. PRODUCT PORTFOLIO
10.2.4. REVENUE ANALYSIS
10.2.5. ANALYSTS VIEW
10.3. CESCA THERAPEUTICS
10.3.1. OVERVIEW
10.3.2. SWOT ANALYSIS
10.3.3. PRODUCT PORTFOLIO
10.3.4. REVENUE ANALYSIS
10.3.5. ANALYST VIEW
10.4. DEPUY SYNTHES
10.4.1. OVERVIEW
10.4.2. SWOT ANALYSIS
10.4.3. PRODUCT PORTFOLIO
10.4.4. REVENUE ANALYSIS
10.4.5. ANALYSTS VIEW
10.5. DMP SPINE
10.5.1. OVERVIEW
10.5.2. SWOT ANALYSIS
10.5.3. PRODUCT PORTFOLIO
10.5.4. REVENUE ANALYSIS
10.5.5. ANALYSTS VIEW
10.6. DR. PRP AMERICA LLC.
10.6.1. OVERVIEW
10.6.2. SWOT ANALYSIS
10.6.3. PRODUCT PORTFOLIO
10.6.4. REVENUE ANALYSIS
10.6.5. ANALYSTS VIEW
10.7. EXACTECH, INC.
10.7.1. OVERVIEW
10.7.2. SWOT ANALYSIS
10.7.3. PRODUCT PORTFOLIO
10.7.4. REVENUE ANALYSIS
10.7.5. ANALYSTS VIEW
10.8. K2M, INC.
10.8.1. OVERVIEW
10.8.2. SWOT ANALYSIS
10.8.3. PRODUCT PORTFOLIO
10.8.4. REVENUE ANALYSIS
10.1.5. ANALYSTS VIEW
10.9. LATTICE BIOLOGICS
10.9.1. OVERVIEW
10.9.2. SWOT ANALYSIS
10.9.3. PRODUCT PORTFOLIO
10.9.4. REVENUE ANALYSIS
10.9.5. ANALYSTS VIEW
10.10. MEDTRONIC
10.10.1. OVERVIEW
10.10.2. SWOT ANALYSIS
10.10.3. PRODUCT PORTFOLIO
10.10.4. REVENUE ANALYSIS
10.10.5. ANALYSTS VIEW
10.11. NUVASIVE, INC.
10.11.1. OVERVIEW
10.11.2. SWOT ANALYSIS
10.11.3. PRODUCT PORTFOLIO
10.11.4. REVENUE ANALYSIS
10.11.5. ANALYSTS VIEW
10.12. ORTHOFIX HOLDINGS, INC.
10.12.1. OVERVIEW
10.12.2. SWOT ANALYSIS
10.12.3. PRODUCT PORTFOLIO
10.12.4. REVENUE ANALYSIS
10.12.5. ANALYSTS VIEW
10.13. REGENLAB S.A.
10.13.1. OVERVIEW
10.13.2. SWOT ANALYSIS
10.13.3. PRODUCT PORTFOLIO
10.13.4. REVENUE ANALYSIS
10.13.5. ANALYSTS VIEW
10.14. RTI SURGICAL
10.14.1. OVERVIEW
10.14.2. SWOT ANALYSIS
10.14.3. PRODUCT PORTFOLIO
10.14.4. REVENUE ANALYSIS
10.14.5. ANALYSTS VIEW
10.15. STRYKER CORPORATION
10.15.1. OVERVIEW
10.15.2. SWOT ANALYSIS
10.15.3. PRODUCT PORTFOLIO
10.15.4. REVENUE ANALYSIS
10.15.5. ANALYSTS VIEW
10.16. WRIGHT MEDICAL
10.16.1. OVERVIEW
10.16.2. SWOT ANALYSIS
10.16.3. PRODUCT PORTFOLIO
10.16.4. REVENUE ANALYSIS
10.16.5. ANALYSTS VIEW
10.17. X-SPINE SYSTEMS
10.17.1. OVERVIEW
10.17.2. SWOT ANALYSIS
10.17.3. PRODUCT PORTFOLIO
10.17.4. REVENUE ANALYSIS
10.17.5. ANALYSTS VIEW
10.18. ZIMMER BIOMET
10.18.1. OVERVIEW
10.18.2. SWOT ANALYSIS
10.18.3. PRODUCT PORTFOLIO
10.18.4. REVENUE ANALYSIS
10.18.5. ANALYSTS VIEW
11. APPENDIX
12. ABOUT DATA BRIDGE MARKET RESEARCH
